• 1
    Loprinzi CL, Dose AM. Studies on the prevention of 5-fluorouracil-induced oral mucositis. Natl Cancer Inst Monogr. 1990; 9: 9394.
  • 2
    Miaskowski C. Management of mucositis during therapy. Natl Cancer Inst Monogr. 1990; 9: 9598.
  • 3
    Bourhis J, Eschwege F. Radiotherapy — chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Anticancer Res. 1996; 16: 23972402.
  • 4
    Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10: 12451251.
  • 5
    Looney W, Hopkins H, Tubiana M. Experimental and clinic studies alternating chemotherapy and radiotherapy. Cancer Metastasis Rev. 1989; 8: 5379.
  • 6
    Tubiana M. The role of local treatment in the cure of cancer. Eur J Cancer. 1992; 28: 20612069.
  • 7
    Gandia D, Wilbaut P, Guillot T, et al. Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous haed and neck cancer. Head Neck. 1993; 15: 815.
  • 8
    Goldie J, Coldman A. Theoretical considerations regarding the early use of adjuvant chemotherapy. In: RapazJ, BankP, GoldieJ. Recent results in cancer research:preoperative (neoadjuvant) chemotherapy. New York: Springer Verlag, 1986: 3035.
  • 9
    Pignon JP, Bourhis J, Domange C, Designe L, on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000; 355: 949955.
  • 10
    Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomize trial. J Clin Oncol. 2000; 17: 14581464.
  • 11
    al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998: 16: 13101317.
  • 12
    Urba S. Concurrent chemoradiation for head and neck cancer. In: PerryMC. American Society of Clinical Oncology educational book. Alexandria, VA: American Society of Clinical Oncology, 2000: 215218.
  • 13
    Forastiere A. Concurrent cisplatinum and radiation for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1995; 31: 679680.
  • 14
    Marcial V, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer. 1990; 66: 18611868.
  • 15
    Denham J, Abbott R. Concurrent cisplatin, infusional fluorouracil and conventionally fractionated radiation therapy in head and neck cancer: dose limiting mucosal toxicity. J Clin Oncol. 1991; 9: 458463.
  • 16
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 90003. Int J Radiat Oncol Biol Phys. 2000; 48: 716.
  • 17
    Withers HR, Peters LJ. Transmutability of dose and time commentary on the first report of RTOG 90003. Int J Radiat Oncol Biol Phys. 2000; 48: 12.
  • 18
    National Institutes of Health consensus development conference on oral complications of cancer therapies: diagnosis, prevention and treatment. Natl Cancer Inst Monogr. 1990; 9: 1184.
  • 19
    Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 1998; 25: 538551.
  • 20
    Berger AM, Kilroy TJ. Oral complications. In: De VitaVT, HellmanS, RosembergSA. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 27142725.
  • 21
    Stein C. Peripheral mechanism of opioid analgesia. Anesth Analg. 1993; 76: 182191.
  • 22
    Fields HL, Emson PC, Leigh BK, Gilbert RFT, Iversen LL. Multiple opiate receptor sites on primary afferent fibres. Nature. 1980; 284: 351353.
  • 23
    LaMotte C, Pert CB, Snyder SH. Opiate receptor binding in primate spinal cord: distribution and changes after dorsal root section. Brain Res. 1976; 112: 407412.
  • 24
    Stein C, Hassan AHS, Przewlocki R, Gramsch C, Peter K, Herz A. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A. 1990; 87: 59355939.
  • 25
    Hassan AHS, Ableitner A, Stein C, Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience. 1993; 55: 185195.
  • 26
    Schafer M, Imai Y, Uhl GR, Stein C. Inflammation enhances peripheral μ-opioid analgesia, but not μ-opioid receptor transcription in dorsal root ganglia. Eur J Pharmacol. 1995; 279: 165169.
  • 27
    Likar R, Koppert W, Blatnig H, et al. Efficacy of peripheral morphine analgesia in inflamed, non-inflamed and perineural tissue of dental surgery patients. J Pain Sympton Manage. 2001; 21: 330337.
  • 28
    World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979: 1522.
  • 29
    Oken MM, Creech RH, Torney DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649655.
  • 30
    Milton JS. Statistical methods in the biological and health sciences. Singapore: McGraw-Hill, 1992.
  • 31
    FlemingID, CooperJS, HensonDE, et al, eds. American Joint Comittee on Cancer staging manual, 5th ed. Philadelphia: JB Lippincott, 1997.
  • 32
    Sonis ST. Mucositis as a biological process a new hypothesis for the development of chemotherapy-induced stomatoxicity. Oral Oncol. 1998; 34: 3943.
  • 33
    Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001; 293: 293297.
  • 34
    Peterson DE. Research advances in oral mucositis. Curr Opin Oncol. 1999; 11: 261266.
  • 35
    Antonijevic I, Mousa SA, Schafer M, Stein C. Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci. 1995; 15: 165172.
  • 36
    Zhou L, Zhang Q, Stein C, Schafer M. Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia. J Pharmacol Exp Ther. 1998; 286: 10001006.
  • 37
    Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med. 1995; 332: 16851690.
  • 38
    Selley DE, Breivogel CS, Childers SR. Modification of G-protein-coupled functions by low pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins. Mol Pharmacol. 1993; 44: 731741.
  • 39
    Beckett AH, Hossie RD. Buccal absorption of drugs. Handbook Exp Pharmacol. 1971; 28: 2446.
  • 40
    Schanker LS. Passage of drugs across body membranes. Pharmacol Rev. 1962; 14: 501530.
  • 41
    Kaufman J, Semo N, Koski W. Microelectrode titration measurements of the pKas and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence. J Med Chem. 1975; 18: 647655.
  • 42
    Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988; 44: 335342.
  • 43
    Ripamonti C, Bruera E. Rectal, buccal and sublingual narcotics for the management of cancer pain. J Palliat Care. 1991; 7: 3035.
  • 44
    Koster WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. Cancer J Clin. 2001; 51: 290315.